Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cian Healthcare's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 164.32.
Cian Healthcare's Days Inventory for the
six
months ended in Mar. 2026 was 211.31.
Cian Healthcare's Days Payable for the
six
months ended in Mar. 2026 was 374.57.
Therefore, Cian Healthcare's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 1.06.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Cian Healthcare Cash Conversion Cycle Related Terms
Cian Healthcare Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Cian Healthcare's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542678 vs ZTS, UTHR, VTRS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cian Healthcare's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cian Healthcare Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cian Healthcare's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Cian Healthcare's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Cian Healthcare's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cian Healthcare (BOM:542678) has a Cash Conversion Cycle of 1.06 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Cian Healthcare and its competitors.
Is Cian Healthcare's Cash Conversion Cycle too high?
Cian Healthcare's current Cash Conversion Cycle is 1.06. The Drug Manufacturers industry median Cash Conversion Cycle is 145.92. Cian Healthcare's value of 1.06 is 99.3% below this industry median. Overall, Cian Healthcare has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cian Healthcare's Cash Conversion Cycle compare to ZTS and UTHR?
Cian Healthcare's Cash Conversion Cycle of 1.06 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.92. Cian Healthcare's value of 1.06 is 99.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.92, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cian Healthcare's current Cash Conversion Cycle of 1.06 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Cian Healthcare and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cian Healthcare's current Cash Conversion Cycle is 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cian Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Cian Healthcare (BOM:542678) is currently considered Possible Value Trap. The stock's GF Value™ is ₹82.33, compared to a current price of ₹9.55 — trading 88.4% below its estimated fair value. The current Cash Conversion Cycle is 1.06 and 99.3% below the Drug Manufacturers industry median of 145.92. Cian Healthcare's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Cian Healthcare (BOM:542678), the current Cash Conversion Cycle is 1.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cian Healthcare (BOM:542678) Overvalued in 2026?
Based on GuruFocus' analysis, Cian Healthcare stock appears to be undervalued.
The current stock price of ₹9.55 is trading 88.4% below its estimated GF Value™ of ₹82.33.
GuruFocus considers Cian Healthcare to be Possible Value Trap.
Key valuation signals for BOM:542678:
Cash Conversion Cycle: 1.06
GF Value™: ₹82.33 vs. price of ₹9.55 (88.4% below fair value)
Industry Position: 99.3% below the Drug Manufacturers median
No single metric tells the full story. See the BOM:542678 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cian Healthcare Ltd is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company manufactures multiple product lines, including tablets, capsules, soft gels, liquid orals, ointments/creams and sachets, and cosmetics. Its portfolio comprises gynecology, haematinic, cardio-diabetic, orthopedic, pediatric, dermacosmetic, antibiotic, CNS, vitamins, and nutrient products. The company operates in five sectors: Export, Government Supplies, Merchant Export, Own Brand Franchise Business, and Third Party/Contract Manufacturing.
49GF Score
Get the complete analysis for BOM:542678
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542678 has been successfully added to your 
